- Home
- Products
- Customized FluoroAb™
- ERBB2
- Anti-ERBB2 MAb (Clone 19)-iFluor® 488 Succinimidyl Ester
Anti-ERBB2 MAb (Clone 19)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9728)
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; neuro/glioblastoma derived oncogene homolog (avian); NGL; v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-prEGF receptor family members to form a heterodimer; stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways; such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported; with the most common allele; Ile654/Ile655; shown he
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Humanized Anti-ERBB2 Antibody (Clone 19)
- Species Reactivity
- Human
- Name
- iFluor® 488 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 491/516
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS9728. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-116 | Anti-ERBB2 (Trastuzumab)-Gly5-modified DM1 ADC | C-terminal GS (glycine-serine) linker | Gly5-modified DM1 (Gly5-modified N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1116 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1114 | Anti-ERBB2 (Pertuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1117 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD22 MAb (Clone 14)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS6559)
- Anti-MYL MAb (Clone 9)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS12376)
- Anti-TAG-72 MAb (Clone 4)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS9255)
- Anti-C5 MAb (Clone 16)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS10901)
- Anti-FN1 MAb (Clone 5)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4126)
- Anti-CD4 MAb (Clone 21)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1154)
- Anti-SOST MAb (Clone 7)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16876)
- Anti-TPBG MAb (Clone 10)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3415)
- Crenezumab-iFluor 532 (CAT#: ADC-FL-112)
- Anti-KDR MAb (Clone 4)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11420)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.